SPEAR

Spear Bio is a biotechnology company specializing in ultrasensitive protein detection and proteomics. Spun out from Harvard’s Wyss Institute in 2021, the company leverages its proprietary Successive Proximity Extension Amplification Reaction (SPEAR) technology to quantify low-abundance biomarkers from extremely small sample volumes, such as dried blood spots. Its platform offers sensitivity levels two to three orders of magnitude higher than traditional digital immunoassays and is compatible with standard qPCR instrumentation. Spear Bio's initial product offerings focus on neurodegenerative disease biomarkers and infectious disease monitoring, aiming to democratize access to high-precision diagnostics.